Etomerzol for Health & Longevity

Created on 10/29/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Etomerzol, a Soviet-era synthetic compound never approved as a medicine, was designed to help the body withstand heavy exertion, oxygen shortage and poisoning. Its developers' small early studies point toward faster poisoning recovery and better endurance under extreme strain, but no independent group has repeated them. The injectable form harmed injection sites, rats developed liver and kidney damage after about two weeks, and long-term safety for healthy adults is unknown. (Full Review)

Protocol

No longevity protocol
None defined
No practitioner, guideline or trial defines use for health or longevity
Clinical regimen (injection)
80 mg intramuscularly, once or twice daily
2 mL of 4% solution, started on day 1–2 of poisoning
Oral use
No human oral dose studied
Rats received 50 mg/kg orally for 10 days; rat doses do not translate directly to humans
Time to effect
Poisoning recovery
Day 3–5
Recovery differences emerged in poisoned patients
Function normalized
Day 7–10
Day 7 in moderate and day 10 in severe poisoning, vs day 11 and 16 with standard care alone
Endurance
Within a single session
Healthy volunteers during 6–24-hour exertion

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Liver or kidney impairment
  • Bleeding disorders, thrombocytopenia or upcoming surgery
  • People prone to hypoglycemia
  • Children and adolescents
Key Interactions
  • Organophosphate insecticide poisoning (malathion): accumulation
Theoretical (inferred from mechanism)
  • Anticoagulants and antiplatelet drugs (warfarin, aspirin): increased bleeding risk
  • NSAIDs (ibuprofen, naproxen): gastrointestinal or other bleeding
  • Calcium channel blockers (amlodipine) and other antihypertensives (lisinopril): low blood pressure, dizziness
  • Narrow-margin drugs cleared by CYP1A (theophylline, warfarin): lower drug levels
  • Glucose-lowering drugs (insulin, sulfonylureas): hypoglycemia
  • Barbiturates (phenobarbital): unpredictable sedation
  • Stimulants (caffeine, modafinil): irritability, disrupted sleep
  • Supplements with antiplatelet effects (fish oil, ginkgo): bleeding risk
  • Supplements that lower blood pressure (magnesium, beetroot nitrate): low blood pressure, dizziness
  • Other actoprotectors and antihypoxants (bemitil, meldonium): unpredictable additive stimulation and liver load

Risk & Side Effects

  • High:
  • Medium:
  • Low: Injection-site injury, digestive upset and overstimulation
  • Speculative: Liver and kidney damage with repeated dosing, platelet count swings, bleeding tendency, low blood pressure

Monitoring

Marker Target Why
ALT 7–56 U/L Liver injury seen in rats
AST 10–40 U/L Liver injury
Total bilirubin 0.1–1.2 mg/dL Liver processing function
Creatinine 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women Kidney-tubule damage
Platelet count 150–450 ×10⁹/L Platelet swings and bleeding risk
Blood pressure No established target; track change from own baseline Low blood pressure
Endurance benchmark (timed run or ride) Improvement from own baseline Defines success

Cadence: Baseline before any exposure; laboratory tests at day 7 and at the end of a course, then 2–4 weeks after stopping if any value changed; blood pressure daily during the first 3 days

Qualitative Assessment

  • Injection-site pain, redness or hardening (if injected)
  • Perceived exertion and recovery after long efforts
  • Sleep onset and duration
  • Dizziness on standing
  • Unusual bruising or gum bleeding